Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Jasper Therapeutics, Inc. (JSPR : NSDQ)
 
 • Company Description   
Jasper Therapeutics Inc., a biotechnology company focused on hematopoietic cell transplant therapies. Jasper Therapeutics Inc., formerly known as Amplitude Healthcare Acquisition Corporation, is based in REDWOOD CITY, Calif.

Number of Employees: 25

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.97 Daily Weekly Monthly
20 Day Moving Average: 68,329 shares
Shares Outstanding: 37.87 (millions)
Market Capitalization: $112.49 (millions)
Beta: 0.52
52 Week High: $18.88
52 Week Low: $2.45
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 9.19% 19.64%
12 Week -34.72% -29.17%
Year To Date -62.17% -55.01%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2200 BRIDGE PKWY SUITE #102
-
REDWOOD CITY,CA 94065
USA
ph: 650-549-1400
fax: -
ir@jaspertherapeutics.com https://jaspertherapeutics.com
 
 • General Corporate Information   
Officers
Ronald Martell - President; Chief Executive Officer
William Lis - Chairman of the Board
Jeet Mahal - Chief Financial Officer and Chief Business Officer
Kurt von Emster - Director
Christian W.Nolet - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 471871103
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 37.87
Most Recent Split Date: (:1)
Beta: 0.52
Market Capitalization: $112.49 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.37 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.30 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.65
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -73.06
12/31/21 - -94.39
09/30/21 - -201.97
ROA
03/31/22 - -42.32
12/31/21 - -37.09
09/30/21 - -32.52
Current Ratio
03/31/22 - 12.36
12/31/21 - 10.95
09/30/21 - 11.18
Quick Ratio
03/31/22 - 12.36
12/31/21 - 10.95
09/30/21 - 11.18
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 1.80
12/31/21 - 1.84
09/30/21 - 2.08
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©